SeaCrest Wealth Management LLC Sells 23,336 Shares of Johnson & Johnson (NYSE:JNJ)

SeaCrest Wealth Management LLC trimmed its position in Johnson & Johnson (NYSE:JNJ) by 48.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 24,813 shares of the company’s stock after selling 23,336 shares during the period. SeaCrest Wealth Management LLC’s holdings in Johnson & Johnson were worth $3,925,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Naviter Wealth LLC boosted its stake in Johnson & Johnson by 43.8% in the first quarter. Naviter Wealth LLC now owns 20,281 shares of the company’s stock valued at $3,208,000 after acquiring an additional 6,174 shares in the last quarter. Quattro Financial Advisors LLC boosted its stake in Johnson & Johnson by 27,610.8% in the first quarter. Quattro Financial Advisors LLC now owns 43,506 shares of the company’s stock valued at $6,882,000 after acquiring an additional 43,349 shares in the last quarter. MV Capital Management Inc. lifted its stake in shares of Johnson & Johnson by 5.3% during the first quarter. MV Capital Management Inc. now owns 18,942 shares of the company’s stock worth $2,996,000 after buying an additional 947 shares during the period. Woodmont Investment Counsel LLC lifted its stake in shares of Johnson & Johnson by 2.9% during the first quarter. Woodmont Investment Counsel LLC now owns 81,823 shares of the company’s stock worth $12,944,000 after buying an additional 2,318 shares during the period. Finally, Exchange Capital Management Inc. lifted its stake in shares of Johnson & Johnson by 32.2% during the first quarter. Exchange Capital Management Inc. now owns 16,052 shares of the company’s stock worth $2,539,000 after buying an additional 3,912 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently commented on JNJ shares. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Sunday. Morgan Stanley lowered their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 17th. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Bank of America lowered their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Monday. Eight investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $174.07.

Johnson & Johnson Stock Down 0.3 %

JNJ opened at $145.62 on Thursday. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The company has a fifty day moving average of $148.02 and a two-hundred day moving average of $153.91. The stock has a market capitalization of $350.46 billion, a price-to-earnings ratio of 9.08, a PEG ratio of 2.43 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The company had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. During the same quarter in the previous year, the company earned $2.68 earnings per share. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. On average, research analysts expect that Johnson & Johnson will post 10.62 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were given a $1.24 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date was Monday, May 20th. This represents a $4.96 annualized dividend and a dividend yield of 3.41%. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.